At a glance
ClinicalIndex Comparison RecordPhase 2Active· 86 enrolled
Drug / intervention
Follow-Up Care +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Metastasectomy Study for Patients With Renal Cell Carcinoma
In Brief
A Phase 2 clinical trial evaluating Follow-Up Care and Laboratory Biomarker Analysis for Renal Cell Carcinoma. Active but no longer recruiting, targeting 86 participants across 1 site.
Detailed Summary
This phase II trial studies the follow-up after metastasectomy in patients with kidney cancer. Following up patients' health condition after metastasectomy may help doctors to learn if the surgical removal of the primary tumor or the parts of the cancer that has spread to other parts of the body is a good method for treating patients who have kidney cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Cell Carcinoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2Active
2009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2009
First PostedJun 2009
TodayJul 2026
Primary CompletionDec 2026
First PostedJun 11, 2009
Enrollment StartJun 9, 2009
Primary CompletionDec 20, 2026
TodayJul 1, 2026
Enrollment to primary: 17.5 yearsPosted 17.1 years agoPrimary completion in 6 months
Interventions
Follow-Up Careother
Undergo follow-up
Laboratory Biomarker Analysisother
Correlative studies